Amgen (AMGN) Competitors

Moderna has a beta of 1.1, suggesting that its stock price is 10% more volatile than the broader market. Comparatively, Amgen has a beta of 0.43, suggesting that its stock price is 57% less volatile than the broader market.

Amgen has a net margin of 22.95% compared to Moderna's net margin of -141.43%. Amgen's return on equity of 124.14% beat Moderna's return on equity.

In the previous week, Moderna had 21 more articles in the media than Amgen. MarketBeat recorded 76 mentions for Moderna and 55 mentions for Amgen. Amgen's average media sentiment score of 0.90 beat Moderna's score of 0.53 indicating that Amgen is being referred to more favorably in the news media.

Moderna currently has a consensus price target of $76.72, indicating a potential downside of 47.29%. Amgen has a consensus price target of $381.68, indicating a potential downside of 12.71%. Given Amgen's stronger consensus rating and higher probable upside, analysts plainly believe Amgen is more favorable than Moderna.

Amgen has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

75.3% of Moderna shares are held by institutional investors. Comparatively, 76.5% of Amgen shares are held by institutional investors. 10.8% of Moderna shares are held by company insiders. Comparatively, 0.9% of Amgen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Vertex Pharmaceuticals has a beta of 0.32, meaning that its stock price is 68% less volatile than the broader market. Comparatively, Amgen has a beta of 0.43, meaning that its stock price is 57% less volatile than the broader market.

91.0% of Vertex Pharmaceuticals shares are owned by institutional investors. Comparatively, 76.5% of Amgen shares are owned by institutional investors. 0.2% of Vertex Pharmaceuticals shares are owned by insiders. Comparatively, 0.9% of Amgen shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Amgen has higher revenue and earnings than Vertex Pharmaceuticals. Amgen is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

In the previous week, Amgen had 28 more articles in the media than Vertex Pharmaceuticals. MarketBeat recorded 55 mentions for Amgen and 27 mentions for Vertex Pharmaceuticals. Vertex Pharmaceuticals' average media sentiment score of 1.38 beat Amgen's score of 0.90 indicating that Vertex Pharmaceuticals is being referred to more favorably in the media.

Vertex Pharmaceuticals presently has a consensus target price of $569.52, indicating a potential upside of 4.29%. Amgen has a consensus target price of $381.68, indicating a potential downside of 12.71%. Given Vertex Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Vertex Pharmaceuticals is more favorable than Amgen.

Vertex Pharmaceuticals has a net margin of 35.00% compared to Amgen's net margin of 22.95%. Amgen's return on equity of 124.14% beat Vertex Pharmaceuticals' return on equity.

In the previous week, AbbVie had 103 more articles in the media than Amgen. MarketBeat recorded 158 mentions for AbbVie and 55 mentions for Amgen. AbbVie's average media sentiment score of 1.34 beat Amgen's score of 0.90 indicating that AbbVie is being referred to more favorably in the media.

Amgen has lower revenue, but higher earnings than AbbVie. Amgen is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Amgen has a net margin of 22.95% compared to AbbVie's net margin of 9.80%. Amgen's return on equity of 124.14% beat AbbVie's return on equity.

70.2% of AbbVie shares are owned by institutional investors. Comparatively, 76.5% of Amgen shares are owned by institutional investors. 0.1% of AbbVie shares are owned by company insiders. Comparatively, 0.9% of Amgen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

AbbVie pays an annual dividend of $6.92 per share and has a dividend yield of 2.7%. Amgen pays an annual dividend of $10.08 per share and has a dividend yield of 2.3%. AbbVie pays out 195.5% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Amgen pays out 62.6% of its earnings in the form of a dividend. AbbVie has raised its dividend for 53 consecutive years and Amgen has raised its dividend for 14 consecutive years. AbbVie is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

AbbVie has a beta of 0.29, suggesting that its share price is 71% less volatile than the broader market. Comparatively, Amgen has a beta of 0.43, suggesting that its share price is 57% less volatile than the broader market.

AbbVie presently has a consensus price target of $275.95, indicating a potential upside of 7.68%. Amgen has a consensus price target of $381.68, indicating a potential downside of 12.71%. Given AbbVie's stronger consensus rating and higher possible upside, equities analysts clearly believe AbbVie is more favorable than Amgen.

Amgen currently has a consensus price target of $381.68, indicating a potential downside of 12.71%. Astrazeneca has a consensus price target of $206.67, indicating a potential upside of 27.09%. Given Astrazeneca's stronger consensus rating and higher probable upside, analysts clearly believe Astrazeneca is more favorable than Amgen.

Amgen pays an annual dividend of $10.08 per share and has a dividend yield of 2.3%. Astrazeneca pays an annual dividend of $4.34 per share and has a dividend yield of 2.7%. Amgen pays out 62.6% of its earnings in the form of a dividend. Astrazeneca pays out 64.9% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Amgen has increased its dividend for 14 consecutive years.

Amgen has a beta of 0.43, meaning that its stock price is 57% less volatile than the broader market. Comparatively, Astrazeneca has a beta of 0.25, meaning that its stock price is 75% less volatile than the broader market.

In the previous week, Amgen had 39 more articles in the media than Astrazeneca. MarketBeat recorded 55 mentions for Amgen and 16 mentions for Astrazeneca. Amgen's average media sentiment score of 0.90 beat Astrazeneca's score of 0.51 indicating that Amgen is being referred to more favorably in the media.

Astrazeneca has higher revenue and earnings than Amgen. Astrazeneca is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Amgen has a net margin of 22.95% compared to Astrazeneca's net margin of 17.02%. Amgen's return on equity of 124.14% beat Astrazeneca's return on equity.

76.5% of Amgen shares are owned by institutional investors. Comparatively, 20.4% of Astrazeneca shares are owned by institutional investors. 0.9% of Amgen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.